Fidaxomicin's narrow-spectrum activity is highly beneficial in the context of antibiotic stewardship and the reduction of antibiotic resistance. By specifically targeting C. difficile, fidaxomicin preserves the normal gut microbiota, which is often disrupted by broad-spectrum antibiotics. This helps in reducing the incidence of secondary infections and the spread of antibiotic-resistant bacteria.
